<DOC>
	<DOCNO>NCT00146562</DOCNO>
	<brief_summary>The main purpose study see pegfilgrastim ( Neulasta ) safe useful support people dose-dense chemotherapy , see long-acting red blood cell growth factor , darbepoetin alfa ( Aranesp ) reduce need blood transfusion chemotherapy recipient .</brief_summary>
	<brief_title>Pegfilgrastim Darbepoetin Alfa Support Adjuvant Chemotherapy Breast Cancer</brief_title>
	<detailed_description>- Patients receive chemotherapy every 2 week 8 cycle ( spread approximately 16 week , total ) treatment . On day chemotherapy treatment patient may receive injection darbepoetin alfa addition chemotherapy red blood cell count normal level . - On day chemotherapy treatment , patient receive injection pegfilgrastim . There one pegfilgrastim shot give per treatment cycle , total 8 injection . Once patient finish chemotherapy last pegfilgrastim shot , participation trial complete . - While study follow procedure perform : physical exam do every 2 week , vital sign do every 2 week , blood test every 2 week . - This study also involve Quality Life Questionnaire do begin study treatment , 2 month , 4 month , 6 month , 1 year start study treatment . - Patients remain study unless experience unacceptable side effect treatment drug .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer clinical stage I , II III disease . Patients must deem sufficient risk tumor recurrence Patients may receive define adjuvant chemotherapy treatment either follow definitive breast surgery prior definitive breast surgery 18 year age old ECOG performance status 0 1 ANC &gt; 1,500/uL Hemoglobin &gt; 9 g/dL Platelets &gt; 100,000/ul Total bilirubin less equal ULN AST/ALT &lt; 1.5 x ULN Creatinine within normal institutional limit PT/PTT &lt; institutional upper limit normal LVEF &gt; 50 % Previous cytotoxic chemotherapy therapeutic radiation therapy Pregnant lactate woman Receiving investigational agent Stage IV breast cancer History allergic reaction attribute compound similar chemical biologic composition pegfilgrastim darbepoetin Previous exposure GCSF pegfilgrastim recombinant erythropoetinrelated growth factor . On antibiotic within 72 hour registration Patients immune deficiency increase risk lethal infection treat marrowsuppressive therapy , HIVpositive patient receive antiretroviral therapy Sickle cell disease Known positive antibody response erythropoietic agent Known hematologic disease Known history hyperviscosity syndrome Patients lithium RBC transfusion within past 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>G-CSF</keyword>
	<keyword>pegfilgrastim</keyword>
	<keyword>darbepoetin alfa</keyword>
</DOC>